Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly.

Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly.

Publication date: Jan 20, 2024

Considerable progress has been made in understanding the molecular host-virus battlefield during SARS-CoV-2 infection. Nevertheless, the assembly and egress of newly formed virions are less understood. To identify host proteins involved in viral morphogenesis, we characterize the proteome of SARS-CoV-2 virions produced from A549-ACE2 and Calu-3 cells, isolated via ultracentrifugation on sucrose cushion or by ACE-2 affinity capture. Bioinformatic analysis unveils 92 SARS-CoV-2 virion-associated host factors, providing a valuable resource to better understand the molecular environment of virion production. We reveal that G3BP1 and G3BP2 (G3BP1/2), two major stress granule nucleators, are embedded within virions and unexpectedly favor virion production. Furthermore, we show that G3BP1/2 participate in the formation of cytoplasmic membrane vesicles, that are likely virion assembly sites, consistent with a proviral role of G3BP1/2 in SARS-CoV-2 dissemination. Altogether, these findings provide new insights into host factors required for SARS-CoV-2 assembly with potential implications for future therapeutic targeting.

Open Access PDF

Concepts Keywords
A549 Assembly
Battlefield Cov
Bioinformatic Factors
Valuable G3bp1
Viral Host


Type Source Name
disease IDO host
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
drug DRUGBANK Sucrose
drug DRUGBANK Tropicamide
disease IDO production
disease VO time
disease IDO replication
drug DRUGBANK L-Citrulline
disease IDO facility
pathway KEGG Viral replication
disease MESH infection
disease VO Viruses
disease IDO infectivity
disease IDO assay
drug DRUGBANK Coenzyme M
disease VO titer
pathway KEGG Ribosome
pathway KEGG Proteasome
drug DRUGBANK Methylergometrine
drug DRUGBANK Biotin
drug DRUGBANK Serine
disease MESH viral infections
disease VO viability
disease VO population
disease IDO cell
disease VO dose
disease IDO process
drug DRUGBANK Esomeprazole
disease VO Chikungunya virus
disease VO Dengue virus
disease MESH shock
disease VO efficiency
disease VO organization
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Glutamic Acid
disease MESH lung adenocarcinoma
drug DRUGBANK Amino acids
disease VO storage
pathway KEGG Apoptosis
drug DRUGBANK Puromycin
drug DRUGBANK Tromethamine
drug DRUGBANK Edetic Acid
drug DRUGBANK L-Phenylalanine
drug DRUGBANK Sodium lauryl sulfate
disease VO protocol
drug DRUGBANK Trypsin
drug DRUGBANK Flunarizine
drug DRUGBANK Formic Acid
disease MESH Dissociation
disease VO device
disease VO Gap
disease IDO homo sapiens
disease IDO quality
disease IDO site

Original Article

(Visited 1 times, 1 visits today)